Bailard Inc. Sells 15,400 Shares of Bioventus Inc. (NYSE:BVS)

Bailard Inc. decreased its stake in Bioventus Inc. (NYSE:BVS) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,700 shares of the company’s stock after selling 15,400 shares during the period. Bailard Inc.’s holdings in Bioventus were worth $322,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp grew its stake in Bioventus by 37.4% in the fourth quarter. Bank of New York Mellon Corp now owns 125,055 shares of the company’s stock valued at $1,313,000 after purchasing an additional 34,036 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Bioventus by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock valued at $202,000 after buying an additional 1,652 shares during the last quarter. Spire Wealth Management bought a new position in shares of Bioventus in the fourth quarter valued at $402,000. JPMorgan Chase & Co. increased its holdings in Bioventus by 228.3% during the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after buying an additional 176,442 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in Bioventus during the third quarter worth $1,011,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Insider Transactions at Bioventus

In related news, CEO Robert E. Claypoole sold 28,786 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the transaction, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This trade represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the completion of the sale, the chief financial officer now directly owns 105,162 shares of the company’s stock, valued at $1,107,355.86. This represents a 9.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,932 shares of company stock worth $512,511. Company insiders own 32.90% of the company’s stock.

Bioventus Stock Down 0.6 %

Bioventus stock opened at $10.09 on Wednesday. The company’s 50-day moving average price is $10.23 and its two-hundred day moving average price is $10.99. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock has a market cap of $818.85 million, a P/E ratio of -16.54 and a beta of 0.85. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.